Skip to main content
Erschienen in: Pathology & Oncology Research 1/2018

12.02.2017 | Letter to the Editor

Dual Immunohistochemical Detection of Mitoses in Melanoma

verfasst von: Thomas M. Soike, John C. Maize, Jonathan S. Ralston, Benjamin Hayes, Julie Swick

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Mitotic rate in melanoma is the second most powerful independent predictor of survival outcome after tumor thickness [1]. The mitotic rate plays a critical role in the 2008 American Joint Committee on Cancer (AJC) TMN staging on melanoma [2]. Mitosis can be obscured by mitotic mimickers such as apoptosis, karyorrhectic debris, and mitosis in non-melanocytic cells make the definitive determination of mitotic rate difficult. The immunohistochemical stain phosphohistone H3 is expressed nearly exclusively by cells during the metaphase component of the cell cycle [3, 4]. The metaphase component of the cell cycle is characterized chromosomal condensation and coiling. The metaphase component of the cell cycle is recognizable in H&E stained tissue through identification of mitotic figures. The antigen expression during this exclusive period of cell division creates an ideal nuclear target for immunohistochemical detection of mitotic figures. PHH3 is expressed in nearly all cells during metaphase so an additional marker is necessary to properly identify the mitotically active cells of interest. Melanoma-associated antigen recognized by T cells (MART-1) provides another useful target as this antigen’s target is expressed in the cytoplasm of melanocytes [5]. Combining the sensitivity and specificity of PHH3 for mitotic figures and the sensitivity of MART-1 for melanosomes, cells that are dual stained with both antigens can reliably be quantified as mitotic figures in melanocytes. This dual stain approach allows the user to ignore the cells only staining with PHH3 during the mitotic count as they represent mitotically active cells that are not melanocytes. …
Literatur
1.
Zurück zum Zitat Blach C, Soong SJ, Gershenwal JE (2001) Prognostic factors analsyis of 17,600 melanoma patients: validation of the AMerican joint Commision on cancer melanoma staging system. Am J Clin Oncol 19:3622–3634CrossRef Blach C, Soong SJ, Gershenwal JE (2001) Prognostic factors analsyis of 17,600 melanoma patients: validation of the AMerican joint Commision on cancer melanoma staging system. Am J Clin Oncol 19:3622–3634CrossRef
2.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual (7th ed). New York, NY: Springer; 2010 Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual (7th ed). New York, NY: Springer; 2010
3.
Zurück zum Zitat Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31(1):13–20CrossRefPubMed Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31(1):13–20CrossRefPubMed
4.
Zurück zum Zitat Hendzel M (1997) Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 6:348–360CrossRef Hendzel M (1997) Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 6:348–360CrossRef
5.
Zurück zum Zitat Kawakami Y, Eliyahu S, Delgado C, Robbins P (1994) Cloning of the Gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 91(9):3515–3519CrossRefPubMedPubMedCentral Kawakami Y, Eliyahu S, Delgado C, Robbins P (1994) Cloning of the Gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 91(9):3515–3519CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Ponti G, Pollio A, Cesinaro AM, Pellecani G (2012) Value and prognostic significance of mitotic rate in a retrospective series of pT1 cutaneous malignant melanoma patients. Cancer Epidemiol 36:303–305CrossRefPubMed Ponti G, Pollio A, Cesinaro AM, Pellecani G (2012) Value and prognostic significance of mitotic rate in a retrospective series of pT1 cutaneous malignant melanoma patients. Cancer Epidemiol 36:303–305CrossRefPubMed
7.
Zurück zum Zitat Kesmodel S, Karakouisis C, Botbyl J, Canter R (2005) Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 12:449–458CrossRefPubMed Kesmodel S, Karakouisis C, Botbyl J, Canter R (2005) Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 12:449–458CrossRefPubMed
8.
Zurück zum Zitat Shibata K, Ajiro K (1993) Cell cycle-dependent suppressive effect of histone H1 on mitosis-specific H3 phosphorylation. J Biol Chem 25:18431–18434 Shibata K, Ajiro K (1993) Cell cycle-dependent suppressive effect of histone H1 on mitosis-specific H3 phosphorylation. J Biol Chem 25:18431–18434
9.
Zurück zum Zitat Ikenberg K, Pfaltz M, Rakozy C, Kempf W (2012) Immunohistochemical dual staining as an adjunct in assessment of mitotic activity in melanoma. J Cutan Pathol 324-330 Ikenberg K, Pfaltz M, Rakozy C, Kempf W (2012) Immunohistochemical dual staining as an adjunct in assessment of mitotic activity in melanoma. J Cutan Pathol 324-330
10.
Zurück zum Zitat Schimming TT, Grabellus F, Roner M, Pechlivanis S (2012) pHH3 immunostaining improves Interobserver agreement of mitotic index in thin melanomas. Am J Dermatopathol 34:266–269CrossRefPubMed Schimming TT, Grabellus F, Roner M, Pechlivanis S (2012) pHH3 immunostaining improves Interobserver agreement of mitotic index in thin melanomas. Am J Dermatopathol 34:266–269CrossRefPubMed
11.
Zurück zum Zitat Thareja S, Zager J, Sadhwani D (2014) Analysis of tumor mitotic rate in thin metastatic melanomas compared with thin melanomas without metastasis using both the hematoxylin and eosin and anti-phosphohistone 3 IHC stain. Am J Dermpathol 64-67 Thareja S, Zager J, Sadhwani D (2014) Analysis of tumor mitotic rate in thin metastatic melanomas compared with thin melanomas without metastasis using both the hematoxylin and eosin and anti-phosphohistone 3 IHC stain. Am J Dermpathol 64-67
12.
Zurück zum Zitat Hale CS (2013) Mitotic rate in melanoma prognostic value of immunostaining and computer-assisted image analysis. Am J Surg Pathol 37(6):882–889CrossRefPubMedPubMedCentral Hale CS (2013) Mitotic rate in melanoma prognostic value of immunostaining and computer-assisted image analysis. Am J Surg Pathol 37(6):882–889CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Tatzlaff M, Curry J, Ivan D (2013) Immunodetection of pshophoistone H3 as a surrogate of mitotic figure count and clincial outcome in cutaneous melanoma. Mod Pathol 26:1153–1160CrossRef Tatzlaff M, Curry J, Ivan D (2013) Immunodetection of pshophoistone H3 as a surrogate of mitotic figure count and clincial outcome in cutaneous melanoma. Mod Pathol 26:1153–1160CrossRef
Metadaten
Titel
Dual Immunohistochemical Detection of Mitoses in Melanoma
verfasst von
Thomas M. Soike
John C. Maize
Jonathan S. Ralston
Benjamin Hayes
Julie Swick
Publikationsdatum
12.02.2017
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 1/2018
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0203-9

Weitere Artikel der Ausgabe 1/2018

Pathology & Oncology Research 1/2018 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.